Physician profile
Melissa E Combs
NPI 1245885276
$2,605.93
in general payments reported to CMS, 2019-2025
35 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $242 · 2022: $550 · 2023: $415 · 2024: $844 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,813.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,813.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $205.62 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Ucb, INC. | $204.48 | 2024-2025 | Zilbrysq, Rystiggo, Nayzilam |
| Abbott Laboratories | $192.17 | 2021-2025 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $177.19 | 2024 | Inspire |
| Abbvie INC. | $176.00 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $168.31 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $146.02 | 2024-2025 | |
| Novo Nordisk INC | $128.41 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $106.99 | 2022-2023 | Afrezza |
| Renalytix Ai, INC. | $100.95 | 2022 | |
| Corcept Therapeutics | $99.56 | 2021-2025 | Korlym |
| Medtronic, INC. | $95.03 | 2024-2025 | Minimed 780g |
| Pfizer INC. | $92.71 | 2021-2025 | |
| Glaxosmithkline, LLC. | $76.03 | 2023-2025 | Shingrix, Arexvy |
| Amgen INC. | $73.77 | 2024-2025 | Evenity, Prolia, Otezla |
Show all 35 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Combs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.